Dr. Philip on the Importance of Developing New Drugs for Pancreatic Cancer

Philip A. Philip, MD, PhD, FRCP
Published: Monday, May 08, 2017



Philip A. Philip, MD, PhD, FRCP, professor of Medicine, Wayne State University School of Medicine, clinical professor of Oncology at Barbara Ann Karmanos Cancer Institute, discusses the importance of developing new drugs for patients with pancreatic cancer.

Unlike other chemotherapy-resistant cancers that have seen developments in treatments, pancreatic cancer is lacking beneficial improvements of other treatments, states Philip.

According to Philip, it is expected that pancreatic cancer will be the second leading cause of cancer mortalities by 2020. Most of the patients with pancreatic cancer have metastatic disease, making the only way to control the natural history of the disease is by getting better systemic treatments.
 


Philip A. Philip, MD, PhD, FRCP, professor of Medicine, Wayne State University School of Medicine, clinical professor of Oncology at Barbara Ann Karmanos Cancer Institute, discusses the importance of developing new drugs for patients with pancreatic cancer.

Unlike other chemotherapy-resistant cancers that have seen developments in treatments, pancreatic cancer is lacking beneficial improvements of other treatments, states Philip.

According to Philip, it is expected that pancreatic cancer will be the second leading cause of cancer mortalities by 2020. Most of the patients with pancreatic cancer have metastatic disease, making the only way to control the natural history of the disease is by getting better systemic treatments.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Integrating Novel Targeted Treatment Strategies to Advance Pancreatic Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x